^
    11ms
    Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=16, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Aug 2023
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    IMM27M